Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA(†)

BACKGROUND: We characterized the incidence of central nervous system (CNS) metastases after treatment with trastuzumab emtansine (T-DM1) versus capecitabine–lapatinib (XL), and treatment efficacy among patients with pre-existing CNS metastases in the phase III EMILIA study. PATIENTS AND METHODS: In...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Oncol
Hlavní autoři: Krop, I. E., Lin, N. U., Blackwell, K., Guardino, E., Huober, J., Lu, M., Miles, D., Samant, M., Welslau, M., Diéras, V.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2015
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4679405/
https://ncbi.nlm.nih.gov/pubmed/25355722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu486
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky